Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. The company also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, it offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, a surgical blood salvage system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; OrthoPAT, a perioperative autotranfusion system for orthopedic procedures; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNYSE:HAE
Previous Symbol
CUSIP40502410
Phone781-848-7100
Debt
Debt-to-Equity Ratio0.47
Current Ratio2.92
Quick Ratio2.06
Price-To-Earnings
Trailing P/E Ratio55.00
Forward P/E Ratio44.14
P/E Growth3.56
Sales & Book Value
Annual Sales$903.92 million
Price / Sales5.88
Cash Flow$3.5090 per share
Price / Cash Flow29.31
Book Value$14.08 per share
Price / Book7.30
Profitability
EPS (Most Recent Fiscal Year)$1.87
Net Income$45.57 million
Net Margins2.26%
Return on Equity16.04%
Return on Assets9.36%
Miscellaneous
Employees3,136
Outstanding Shares51,680,000
Market Cap$5.36 billion
OptionableOptionable
Haemonetics (NYSE:HAE) Frequently Asked Questions
What is Haemonetics' stock symbol?
Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."
How will Haemonetics' stock buyback program work?
Haemonetics announced that its Board of Directors has authorized a share repurchase program on Tuesday, February 6th 2018, which allows the company to buyback $260,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Shares buyback programs are often an indication that the company's management believes its shares are undervalued.
How were Haemonetics' earnings last quarter?
Haemonetics Co. (NYSE:HAE) issued its quarterly earnings data on Tuesday, November, 6th. The medical instruments supplier reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.02. The medical instruments supplier earned $241.58 million during the quarter, compared to analyst estimates of $233.44 million. Haemonetics had a return on equity of 16.04% and a net margin of 2.26%. The company's revenue was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.48 EPS. View Haemonetics' Earnings History.
When is Haemonetics' next earnings date?
What guidance has Haemonetics issued on next quarter's earnings?
Haemonetics issued an update on its FY19 earnings guidance on Tuesday, November, 6th. The company provided earnings per share (EPS) guidance of $2.25-2.35 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.29. The company issued revenue guidance of $958.2-$976.2 million, compared to the consensus revenue estimate of $951.91 million.Haemonetics also updated its FY 2018 guidance to $2.25-2.35 EPS.
What price target have analysts set for HAE?
5 analysts have issued 1-year target prices for Haemonetics' stock. Their predictions range from $72.00 to $127.00. On average, they expect Haemonetics' share price to reach $111.00 in the next twelve months. This suggests a possible upside of 7.9% from the stock's current price. View Analyst Price Targets for Haemonetics.
What is the consensus analysts' recommendation for Haemonetics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Haemonetics.
What are Wall Street analysts saying about Haemonetics stock?
Here are some recent quotes from research analysts about Haemonetics stock:
- 1. According to Zacks Investment Research, "Over the past year, Haemonetics has been outperforming its industry. The company has been delivering encouraging performance banking on solid execution of its multi-year turnaround strategy. Continued momentum in new business generation and geographical expansion has helped drive results. The company also seems to be upbeat about the receipt of some major regulatory clearances for the Plasma business. Moreover, a strong cash position boosts investors’ confidence. However, we are disappointed with the fact that despite encouraging growth at the Plasma and Hospitals segments, the company’s sluggish Blood Center business moderated overall growth in the reporting cycle." (10/12/2018)
- 2. Barrington Research analysts commented, "We believe that a full transition of the company’s 20,000 base could add $2 or more per plasma donation (i.e. $70 million plus)." (10/5/2018)
- 3. Morgan Stanley analysts commented, "We are maintaining our Outperform rating for REGENXBIO. Today, after market close, the company reported 1Q18 results and provided an update on its pipeline. Key takeaways include: 1) all programs remain on track, with topline data from both the wet AMD and HoFH trials expected in late 2018; and 2) the two MPS programs are slated to dose the first patients in mid-2018. With two wholly owned assets poised to deliver clinical data in late 2018, a powerful AAV technology platform with >20+ partnered programs (10 of which are in the clinic), and a cash position of $336 million pro forma, we continue to recommend REGENXBIO shares to risk-tolerant investors." (5/9/2018)
Has Haemonetics been receiving favorable news coverage?
Media stories about HAE stock have been trending somewhat negative on Friday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Haemonetics earned a coverage optimism score of -1.4 on InfoTrie's scale. They also assigned news stories about the medical instruments supplier a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an effect on the stock's share price in the near future.
Are investors shorting Haemonetics?
Haemonetics saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 1,355,367 shares, an increase of 55.8% from the October 31st total of 869,934 shares. Based on an average daily trading volume, of 557,627 shares, the days-to-cover ratio is currently 2.4 days. Currently, 2.6% of the shares of the company are sold short. View Haemonetics' Current Options Chain.
Who are some of Haemonetics' key competitors?
Some companies that are related to Haemonetics include ResMed (RMD), ABIOMED (ABMD), Teleflex (TFX), DexCom (DXCM), Hill-Rom (HRC), Insulet (PODD), ICU Medical (ICUI), Globus Medical (GMED), Penumbra (PEN), Integra Lifesciences (IART), Cantel Medical (CMD), Novocure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA) and Glaukos (GKOS).
Who are Haemonetics' key executives?
Haemonetics' management team includes the folowing people:
- Mr. Christopher Simon, CEO, Pres & Director (Age 54)
- Mr. William P. Burke, CFO & Exec. VP
- Ms. Michelle L. Basil, EVP, Gen. Counsel & Sec.
- Ms. Jacqueline Scanlan, Sr. VP of Global HR
- Mr. Dan Goldstein, Principal Accounting Officer, VP & Corp. Controller (Age 41)
Who are Haemonetics' major shareholders?
Haemonetics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.48%), Vanguard Group Inc. (10.87%), Vanguard Group Inc (10.87%), Renaissance Technologies LLC (4.37%), Neuberger Berman Group LLC (2.86%) and Jackson Square Partners LLC (2.78%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Mark W Kroll, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Ronald G Gelbman, Ronald Merriman, Susan Bartlett Foote, Willaim P Burke and William P Mr Burke. View Institutional Ownership Trends for Haemonetics.
Which major investors are selling Haemonetics stock?
HAE stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Fuller & Thaler Asset Management Inc., Hsbc Holdings PLC, Wells Fargo & Company MN, Dimensional Fund Advisors LP, Copper Rock Capital Partners LLC, Acadian Asset Management LLC and Morgan Stanley. Company insiders that have sold Haemonetics company stock in the last year include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Mark W Kroll, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo and William P Mr Burke. View Insider Buying and Selling for Haemonetics.
Which major investors are buying Haemonetics stock?
HAE stock was acquired by a variety of institutional investors in the last quarter, including American Century Companies Inc., Eagle Asset Management Inc., Carillon Tower Advisers Inc., HealthCor Management L.P., Renaissance Technologies LLC, AQR Capital Management LLC, Robeco Institutional Asset Management B.V. and JPMorgan Chase & Co.. View Insider Buying and Selling for Haemonetics.
How do I buy shares of Haemonetics?
Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Haemonetics' stock price today?
One share of HAE stock can currently be purchased for approximately $102.85.
How big of a company is Haemonetics?
Haemonetics has a market capitalization of $5.36 billion and generates $903.92 million in revenue each year. The medical instruments supplier earns $45.57 million in net income (profit) each year or $1.87 on an earnings per share basis. Haemonetics employs 3,136 workers across the globe.
What is Haemonetics' official website?
How can I contact Haemonetics?
Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]
MarketBeat Community Rating for Haemonetics (NYSE HAE)
MarketBeat's community ratings are surveys of what our community members think about Haemonetics and other stocks. Vote "Outperform" if you believe HAE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HAE will underperform the S&P 500 over the long term. You may vote once every thirty days.
